| Name | p44mapk |
|---|---|
| Synonyms | ERK 1; ERK1; ERT 2; ERT2; Extracellular signal regulated kinase 1; Extracellular signal related kinase 1b; Extracellular signal related kinase 1c; HS44KDAP… |
| Name | kinetin |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 8947491 | Patel V, Brown C, Goodwin A, Wilkie N, Boarder MR: Phosphorylation and activation of p42 and p44 mitogen-activated protein kinase are required for the P2 purinoceptor stimulation of endothelial production. Biochem J. 1996 Nov 15;320 ( Pt 1):221-6. Here we show that activation of both these P2 receptor types leads to the phosphorylation and activation of both the p42 and p44 forms of mitogen-activated protein kinase (MAPK). 2-Methylthio-ATP and UTP, selectively activating P2Y1 and P2Y2 purinoceptors respectively, and ATP, a non-selective agonist at these two receptors, stimulate the phosphorylation of both p42mapk and p44mapk, as revealed by Western blots with an antiserum specific for the -phosphorylated forms of the enzymes. |
5(0,0,0,5) | Details |
| 11137857 | Ikeda M, Fukuda A, Takagi M, Morita M, Shimada Y: Inhibitory effect of pentalenolactone on vascular smooth muscle cell proliferation. Eur J Pharmacol. 2001 Jan 5;411(1-2):45-53. A similar result was obtained when PD 98059 (2'-amino-3'-methoxyflavone), an inhibitor of extracellular signal-regulated kinase1/2 (ERK1/2) kinase (MEK1/2), was added to the cells after serum stimulation. |
3(0,0,0,3) | Details |
| 10234573 | Zhang W, Lee JC, Kumar S, Gowen M: ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells. J Bone Miner Res. 1999 Apr;14(4):528-35. The roles of extracellular signal-regulated kinase 1 (ERK1) and cyclin-dependent kinase 2 (Cdk2) kinases in the IGF-1-induced proliferative signaling pathway of human osteosarcoma MG63 cells were investigated using a selective inhibitor of MEK, PD98059, and a Cdk inhibitor, olomoucine. |
2(0,0,0,2) | Details |
| 7549905 | Abraham RT, Acquarone M, Andersen A, Asensi A, Belle R, Berger F, Bergounioux C, Brunn G, Buquet-Fagot C, Fagot D, et al.: Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. . Biol Cell. 1995;83(2-3):105-20. Olomoucine (2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine) has been recently described as a competitive inhibitor (ATP-binding site) of the cell cycle regulating p34cdc2/cyclin B, p33cdk2/cyclin A and p33cdk2/cyclin E kinases, the brain p33cdk5/p35 kinase and the ERK1/MAP-kinase. |
1(0,0,0,1) | Details |